← 產業報告目錄
Global PARP Inhibitors Market
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-22報告編號 INSIGHTACE-15bf813066
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
A CAGR of 12.35% is forecasted for the global Global PARP Inhibitors Market over the assessment period of 2025 through 2034.
PARP Inhibitors encompasses long chains of 17 enzymes that connect many adp-ribose units into a chain and transport them to the target proteins. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Growth is supported by a convergence of factors: rising awareness among end users, continuous product innovation, and the escalating emphasis on efficiency and sustainability within the healthcare sector.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, supported by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global PARP Inhibitors Market Snapshot
Chapter 4. Global PARP Inhibitors Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Drug Type Estimates & Trend Analysis
5.1. by Drug Type & Market Share, 2019 & 2030
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Drug Type:
5.2.1. Olaparib
5.2.2. Niraparib
5.2.3. Rucaparib
5.2.4. Talazoparib
Chapter 6. Market Segmentation 2: by Indication Estimates & Trend Analysis
6.1. by Indication & Market Share, 2019 & 2030
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Indication:
6.2.1. Ovarian Cancer
6.2.2. Breast Cancer
6.2.3. Prostate Cancer
6.2.4. Pancreatic Cancer
Chapter 7. Market Segmentation 3: by Distribution Channel Estimates & Trend Analysis
7.1. by Distribution Channel & Market Share, 2019 & 2030
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Distribution Channel:
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
Chapter 8. PARP Inhibitors Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America PARP Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2022-2030
8.1.2. North America PARP Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2022-2030
8.1.3. North America PARP Inhibitors Market revenue (US$ Million) by Distribution Channel, 2022-2030
8.1.4. North America PARP Inhibitors Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030
8.2. Europe
8.2.1. Europe PARP Inhibitors Market revenue (US$ Million) by Drug Type, 2022-2030
8.2.2. Europe PARP Inhibitors Market revenue (US$ Million) by Indication, 2022-2030
8.2.3. Europe PARP Inhibitors Market revenue (US$ Million) by Distribution Channel, 2022-2030
8.2.4. Europe PARP Inhibitors Market revenue (US$ Million) by country, 2022-2030
8.3. Asia Pacific
8.3.1. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by Drug Type, 2022-2030
8.3.2. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by Indication, 2022-2030
8.3.3. Asia-Pacific PARP Inhibitors Market revenue (US$ Million) by Distribution Channel, 2022-2030
8.3.4. Asia Pacific PARP Inhibitors Market revenue (US$ Million) by country, 2022-2030
8.4. Latin America
8.4.1. Latin America PARP Inhibitors Market revenue (US$ Million) by Drug Type, 2022-2030
8.4.2. Latin America PARP Inhibitors Market revenue (US$ Million) by Indication, 2022-2030
8.4.3. Latin America PARP Inhibitors Market revenue (US$ Million) by Distribution Channel, 2022-2030
8.4.4. Latin America PARP Inhibitors Market revenue (US$ Million) by country, 2022-2030
8.5. Middle East & Africa
8.5.1. Middle East & Africa PARP Inhibitors Market revenue (US$ Million) by Drug Type, 2022-2030
8.5.2. Middle East & Africa PARP Inhibitors Market revenue (US$ Million) by Indication, 2022-2030
8.5.3. Middle East & Africa PARP Inhibitors Market revenue (US$ Million) by Distribution Channel, 2022-2030
8.5.4. Middle East & Africa PARP Inhibitors Market revenue (US$ Million) by country, 2022-2030
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. AstraZeneca
9.2.2. GlaxoSmithKline
9.2.3. Merck Co. & Inc
9.2.4. GlaxoSmithKline plc
9.2.5. AbbVie Inc
9.2.6. Clovis Oncology
9.2.7. Medivation
9.2.8. Johnson & Johnson Services, Inc
9.2.9. Pfizer Inc.
9.2.10. Repare Therapeutics, Inc.
9.2.11. Genentech, Inc.
9.2.12. Artios Pharma
9.2.13. Repare Therapeutics Inc.
9.2.14. Sierra Oncology, Inc.
9.2.15. KaryopharmTherapeutics Inc.
9.2.16. Ono Pharmaceutical Co., Ltd.
9.2.17. Jiangsu Hengrui Medicine Co., Ltd.
9.2.18. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們